MLchartDataset catalogue

Biomed 101

Term · Oncology and biomedicine · MLC-T-ONC-001068

  1. A substance that is being studied for its ability to decrease the side effects of interleukin-2 (IL-2).

  2. An agent binding to the leukotriene B4 receptor, leading to reduced interleukin-2 mediated hypoxia. Biomed 101 does not affect interleukin-2 antitumor activity.

Table 1. Record
IdentifierMLC-T-ONC-001068
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON 
{
  "id": "MLC-T-ONC-001068",
  "term": "Biomed 101",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance that is being studied for its ability to decrease the side effects of interleukin-2 (IL-2).",
    "An agent binding to the leukotriene B4 receptor, leading to reduced interleukin-2 mediated hypoxia. Biomed 101 does not affect interleukin-2 antitumor activity."
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/biomed-101/"
}

Record 3,579 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.